February 18, 2021

Serum Neutralizing Activity Elicited by MRNA-1273 Vaccine — Preliminary Report

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, vaccines, variants

Neutralizing activity of sera from recipients of the 2-dose Moderna vaccine in the phase 1 trial (n=45) were similar against a SARS-CoV-2 pseudovirus bearing the spike protein from the original Wuhan-Hu-1 isolate, the D614G variant, as well as against 20E (EU1), 20A.EU2, N439K-D614G, and mink cluster 5 variants. In contrast, neutralizing titers against the D614G variant decreased 2.7-fold against a pseudovirus with a partial set of the mutations in the B.1.351 variant (mutations K417N, E484K, and N501Y), and by 6.4-fold against the full set of B.1.351 mutations. Sera obtained from 8 participants still neutralized the B.1.351 variant at low dilutions. [EDITORIAL NOTE: This article was summarized as a pre-print on January 25, 2021.]

Wu et al. (Feb 17, 2021). Serum Neutralizing Activity Elicited by MRNA-1273 Vaccine — Preliminary Report. New England Journal of Medicine. https://doi.org/10.1056/NEJMc2102179